Kazia Therapeutics Limited American Depositary Shares (KZIA)
Stock · NASDAQ · Health Care
$13.58as of 8/28/2026
Price chart
Open in TradingViewActive signals
High Beta53.6%
Volume Spike25.0%Support level
$12.61
Industry
Biotechnology: Pharmaceutical Preparations
About KZIA
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isoc…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 6
- Website
- www.kaziatherapeutics.com/
Fundamentals
- 1-day range
- $13.7$15.5
- Market cap
- $141.81M
- P/E (trailing)
- —
- P/E (forward)
- -886.80
- EPS (trailing)
- $-0.02
- Dividend yield
- —
- Beta
- 2.30
- Avg. volume
- 194.3K
- Dividend pay date
- July 14, 2017
52-week range
$4.86$17.4
Forecasts
6 analyst ratings
Buy 91%
Hold 9%
Sell 0%
1-year price forecast
High
$34.73
+155.7%
Median
$30.05
+121.3%
Low
$17.93
+32.0%
Kazia Therapeutics Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- KZIAKazia Therapeutics Limited American Depositary Shares$13.59▼ 19.59%Market cap $141.81MP/E —$4.86$17.4
- MISTMilestone Pharmaceuticals Inc. Common Shares$1.17▼ 2.10%Market cap $139.44MP/E —$1$3.06
- HURATuHURA Biosciences Inc. Common Stock$2.11▼ 1.17%Market cap $136.28MP/E —$0.41$3.43
- GNLXGenelux Corporation Common Stock$2.66▼ 7.64%Market cap $133.62MP/E —$2.29$8.54
- ADCTADC Therapeutics SA Common Shares$1.15▲ 2.68%Market cap $133.55MP/E —$0.7796$4.98
- MENSJyong Biotech Ltd. Ordinary Shares$2.37▲ 3.04%Market cap $152.06MP/E —$1.43$67
- CNTNCanton Strategic Holdings Inc. Common Stock$2.23▼ 5.32%Market cap $154.25MP/E —$1.75$7.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KZIA Kazia Therapeutics Limited American Depositary Shares | $141.81M | — | $13.59 | ▼ 19.59% | $4.86$17.4 |
| MIST Milestone Pharmaceuticals Inc. Common Shares | $139.44M | — | $1.17 | ▼ 2.10% | $1$3.06 |
| HURA TuHURA Biosciences Inc. Common Stock | $136.28M | — | $2.11 | ▼ 1.17% | $0.41$3.43 |
| GNLX Genelux Corporation Common Stock | $133.62M | — | $2.66 | ▼ 7.64% | $2.29$8.54 |
| ADCT ADC Therapeutics SA Common Shares | $133.55M | — | $1.15 | ▲ 2.68% | $0.7796$4.98 |
| MENS Jyong Biotech Ltd. Ordinary Shares | $152.06M | — | $2.37 | ▲ 3.04% | $1.43$67 |
| CNTN Canton Strategic Holdings Inc. Common Stock | $154.25M | — | $2.23 | ▼ 5.32% | $1.75$7.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Kazia Therapeutics Prices ~$40M Offering Of 2.58M American Depositary Shares At $17.825 Per ADSbenzinga · 8/28/2026
- Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29Benzinga · 8/13/2026
- Glioma Market is Set for Tremendous Growth at a CAGR of 15% During the Study Period (2022–2036), as Novel Targeted Therapies and Immunotherapies are Gaining Momentum | DelveInsightYahoo · 8/10/2026
Insider Activity
Insider Actions →Acquired
450.0K
Disposed
0
- Levine James E. · June 19, 2026 · Grant200.0K
- Rao Sudha · June 19, 2026 · Grant250.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.75M
- Total value held
- $12.97M
- Institutional holders
- 23
Top holders this quarter
- Unknown400.0K
- Unknown345.2K
- Unknown200.0K
- Unknown193.1K
- Unknown142.5K
- Unknown135.3K
- Unknown79.8K
- Unknown60.0K
- Unknown50.4K
- Unknown34.3K
See the full, filterable feed with live charts on the MarketWall dashboard.